- Home
- NBH vs CRMD Comparison
NBH vs CRMD Comparison
Compare NBH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$8.01
Company Overview
Basic Information| Metric | NBH | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | 191 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.4M | 626.0M |
| IPO Year | 2002 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NBH | CRMD |
|---|---|---|
| Price | $10.28 | $8.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.83 |
| AVG Volume (30 Days) | 86.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $18.78 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $9.72 | $6.13 |
| 52 Week High | $10.64 | $17.43 |
Technical Indicators
Market Signals| Indicator | NBH | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 56.38 |
| Support Level | $10.11 | $6.28 |
| Resistance Level | $10.36 | $8.74 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 42.50 | 37.09 |
Price Performance
Historical Comparison NBH
CRMD
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.